EMA's PRAC defensive over industry criticism but accepts improvements needed
This article was originally published in SRA
Every time the European Medicines Agency publishes details of meetings organized by its new Pharmacovigilance Risk Assessment Committee, these are anxiously scanned by drug companies keen to know whether any of their products are affected by the agency's signal detection and management programme.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.